on-interventional study of the clinical course of mild to moderate IPF under therapy with Esbriet(R)

• Conditions: Mild to moderate Idiopathic Pulmonary Fibrosis in adults; J84.1; Other interstitial pulmonary diseases with fibrosis

• Registration Number: DRKS00006040
• Lead Sponsor: Roche AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05-15
• Study Completion: 2016-12-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

According to SPMC

Exclusion Criteria

According to SPMC

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical outcome of patients suffering from a mild till moderate IPF after a one-year-therapie with Pirfenidon. The evaluation of the clinical outcome takes place by capturing and evaluating lung function parameters, blood gas analysis and others.

Secondary Outcome Measures

Name	Time	Method
not specified/N/A